MX2016010563A - Formas solidas de un modulador del canal ionico. - Google Patents

Formas solidas de un modulador del canal ionico.

Info

Publication number
MX2016010563A
MX2016010563A MX2016010563A MX2016010563A MX2016010563A MX 2016010563 A MX2016010563 A MX 2016010563A MX 2016010563 A MX2016010563 A MX 2016010563A MX 2016010563 A MX2016010563 A MX 2016010563A MX 2016010563 A MX2016010563 A MX 2016010563A
Authority
MX
Mexico
Prior art keywords
solid forms
ion channel
channel modulator
forms
crystalline
Prior art date
Application number
MX2016010563A
Other languages
English (en)
Inventor
Chiu Anna
V Lapina Olga
I Vlahova Petinka
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of MX2016010563A publication Critical patent/MX2016010563A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Las formas sólidas cristalinas del inhibidor de la corriente tardía de sodio selectiva 4-(pirimidin-2-ilmetil)-7-(4-trifluorome toxi)fenil)-3,4-dihidrobenzo[f][1,4]oxazepin-5(2H)-ona (Compuesto I) se prepararon y caracterizaron en el estado sólido: asimismo se proporcionaron procesos de fabricación y métodos de uso de las formas cristalinas.
MX2016010563A 2014-02-13 2015-02-12 Formas solidas de un modulador del canal ionico. MX2016010563A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461939640P 2014-02-13 2014-02-13
PCT/US2015/015652 WO2015123434A1 (en) 2014-02-13 2015-02-12 Solid forms of an ion channel modulator

Publications (1)

Publication Number Publication Date
MX2016010563A true MX2016010563A (es) 2016-12-12

Family

ID=52597268

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016010563A MX2016010563A (es) 2014-02-13 2015-02-12 Formas solidas de un modulador del canal ionico.

Country Status (16)

Country Link
US (1) US9273038B2 (es)
EP (1) EP3105227A1 (es)
JP (1) JP2017505788A (es)
KR (1) KR20160118358A (es)
CN (1) CN105980380A (es)
AR (1) AR102804A1 (es)
AU (1) AU2015217129A1 (es)
BR (1) BR112016018464A2 (es)
CA (1) CA2881544A1 (es)
EA (1) EA201691360A1 (es)
HK (1) HK1226397A1 (es)
IL (1) IL246959A0 (es)
MX (1) MX2016010563A (es)
SG (1) SG11201606652PA (es)
TW (1) TW201613908A (es)
WO (1) WO2015123434A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2707361T (pt) 2011-05-10 2017-11-28 Gilead Sciences Inc Compostos heterocíclicos fusionados como moduladores do canal de sódio
NO3175985T3 (es) 2011-07-01 2018-04-28
TWI622583B (zh) 2011-07-01 2018-05-01 基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
CN1845918A (zh) * 2003-07-02 2006-10-11 沃泰克斯药物股份有限公司 可用作电压－门控离子通道调节剂的嘧啶
LT2464645T (lt) * 2009-07-27 2017-10-25 Gilead Sciences, Inc. Kondensuoti heterocikliniai junginiai, kaip jonų kanalų moduliatoriai
TWI622583B (zh) 2011-07-01 2018-05-01 基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
CA2862670A1 (en) * 2012-01-27 2013-08-01 Gilead Sciences, Inc. Combination therapies using late sodium ion channel blockers and potassium ion channel blockers

Also Published As

Publication number Publication date
AR102804A1 (es) 2017-03-29
WO2015123434A1 (en) 2015-08-20
EA201691360A1 (ru) 2017-07-31
IL246959A0 (en) 2016-09-29
CA2881544A1 (en) 2015-08-13
EP3105227A1 (en) 2016-12-21
AU2015217129A1 (en) 2016-08-11
US9273038B2 (en) 2016-03-01
JP2017505788A (ja) 2017-02-23
KR20160118358A (ko) 2016-10-11
US20150225383A1 (en) 2015-08-13
TW201613908A (en) 2016-04-16
SG11201606652PA (en) 2016-09-29
CN105980380A (zh) 2016-09-28
HK1226397A1 (zh) 2017-09-29
BR112016018464A2 (pt) 2017-08-08

Similar Documents

Publication Publication Date Title
PH12017550028A1 (en) Solid forms of an ask1 inhibitor
MX2015011576A (es) Composiciones que comprenden compuestos de tienopirimidina y tienopiridina y metodos para usar los mismos.
EP3291338A4 (en) Cathode for lithium-sulfur battery, manufacturing method therefor, and lithium-sulfur battery containing same
EP3416229A4 (en) ELECTROLYTIC SOLUTION FOR A BATTERY WITH A WATER-FREE ELECTROLYTIC SOLUTION AND A BATTERY WITH A WATER-FREE ELECTROLYTIC SOLUTION THEREWITH
EP3240089A4 (en) Sulfide-based solid electrolyte for lithium ion cell, and solid electrolyte compound
MX2017015467A (es) Metodos y composiciones para inhibir la interaccion de menina con proteinas de mll.
PH12016500643A1 (en) New octahydro - cyclobuta [1,2-c;3,4-c`] dipyrrol -2- yl
EP3375859A4 (en) PROCESS FOR CONSTRUCTING A CLASSIFIER AND METHOD FOR DETERMINING LIFE AND DEATH OF CELLS THEREWITH
MY189912A (en) Substituted xanthines and methods of use thereof
EP3403292A4 (en) METHOD FOR ESTIMATING DISCHARGE DURATION DURING HIGH-SPEED BATTERY DISCHARGE
EP3276714A4 (en) Anode slurry for secondary battery for improving dispersibility and reducing resistance, and anode comprising same
EP3511443A4 (en) POSITIVE ELECTROLYSIS OF ALKALINE WATER ELECTROLYSIS AND MANUFACTURING METHOD THEREOF
EP3408814A4 (en) ESTIMATING THE LIFE OF A BATTERY
EP3347501A4 (en) NON-MAGNETIC ALLOYS FOR THE FORMATION OF HEAVY CARBIDES FOR THE MANUFACTURE OF POWDERS
EP3398947A4 (en) CONDENSED HETEROCYCLIC COMPOUND CONTAINING NITROGEN, AS WELL AS PREPARATION METHOD, INTERMEDIATE, COMPOSITION AND APPLICATION THEREOF
EP3354653A4 (en) Fused ring pyrimidine compound, intermediate, and preparation method, composition and use thereof
MX366765B (es) Agonistas de receptores gamma activados por el proliferador de peroxisoma para el tratamiento de esclerósis múltiple.
EP3316379A4 (en) SOLID ELECTROLYTE AND PROCESS FOR PREPARING THE SAME, AND LITHIUM ION BATTERY CONTAINING SAME
EP3492469A4 (en) COMPOUND AS JAK SELECTIVE INHIBITOR, SALT THEREOF AND THERAPEUTIC USE THEREOF
EP3306714A4 (en) Electrode mixture, method for manufacturing same, and secondary battery including same
EP3357123A4 (en) SODIUM-METAL BATTERIES WITH INTERCALATE CATHODE
EP3371845A4 (en) Electrode, battery, and method for manufacturing electrode
EP3083946A4 (en) Depletion of plasmacytoid dendritic cells
MX2016010563A (es) Formas solidas de un modulador del canal ionico.
EP3390369A4 (en) SOLID FORMS OF SUBSTITUTED 5,6-DIHYDRO-6-PHENYLBENZO [F] ISOQUINOLINE-2-AMINE COMPOUNDS